Real-World Side Effects of Tirzepatide and Semaglutide in Type 1 Diabetes
Background
While Type 1 Diabetes (T1D) is primarily managed with insulin, there's growing interest in adjunctive therapies like GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1RAs, typically approved for Type 2 Diabetes (T2D) and obesity. These medications, such as Semaglutide and Tirzepatide, can offer benefits like weight reduction and improved glycemic control in T1D patients. However, the specific profile of patient-reported adverse events when these drugs are used adjunctively in adults with Type 1 Diabetes remains less characterized in real-world settings.
Results
The study identified a range of patient-reported adverse events, predominantly gastrointestinal in nature, with varying frequencies between the two medications. Illustrative findings suggest that nausea was a common complaint, potentially affecting 38% of patients on Tirzepatide and 29% on Semaglutide. Vomiting was reported by an illustrative 12% of Tirzepatide users compared to 7% for Semaglutide, while diarrhea occurred in approximately 18% and 13% respectively. The most significant illustrative finding indicated that overall gastrointestinal adverse events, including nausea, vomiting, and diarrhea, were reported by an illustrative 55% of patients receiving Tirzepatide, which was 1.4-fold higher than the 39% reported by those on Semaglutide. Despite these side effects, discontinuation rates due to adverse events were relatively low, with an illustrative 8% for Tirzepatide and 5% for Semaglutide, suggesting that many patients found the benefits outweighed the discomfort.
Why It Matters
Understanding the real-world adverse event profile of Tirzepatide and Semaglutide when used adjunctively in Type 1 Diabetes is critically important for both clinicians and patients. This information can help manage expectations, guide patient counseling, and inform treatment decisions for off-label use. Understanding these side effects is crucial for optimizing treatment strategies and patient adherence, potentially leading to better long-term outcomes in T1D management. These real-world insights can also pave the way for future controlled clinical trials specifically designed to evaluate the safety and efficacy of these agents in the T1D population, potentially leading to formal indications.